In France, more than 80% of children with Burkitt's lymphoma or Burkitt's leukemia (ALL3) are now cured with the LMB (B-cell non-Hodgkin's lymphoma and B-ALL) protocols of the Societe Franpaise d'Oncologie PBdiatrique, but so far, poor results have been obtained in the few adult studies available. We have analyzed the experience with LMB protocols in adult patients. This retrospective study involved 65 adult patients with small noncleaved cell lymphoma or ALL, treated with the LMB protocols. They were 17 t o 65 years old and not previously treated. Human immunodeficiency virus-infected patients were excluded. MALL NONCLEAVED cell lymphoma (SNCL) accounts for more than a half of the lymphomas seen in non-African children' and for between 5% and 10% of nonHodgkin's lymphomas in adults.' Therefore, most clinical trials have been performed in the pediatric setting."" In France, more than 80% of children with SNCL or Burkitt's leukemia (ALL3) are now cured when treated with the pediatric LMB (B-cell non-Hodgkin's lymphoma and B-ALL) combination chemotherapy regimen.' The few adult trials available have all been small and included few cases of disseminated disease. Results have been poor with overall 2-and 5-year survival rates ranging from 50% to 67%, and decreasing to 0% to 29% in case of bone marrow (BM) or central nervous system (CNS) local irradiation was performed in 4 patients, 2 patients received prophylactic radiation to the brain that was not specified in the protocol, 13 patients underwent BMT in first CR. and methotrexate doses were modified in 10 patients. Fiftyeight patients (89%) achieved a CR. There were four (6%) primary induction treatment failures, and three (4%) early treatment-related deaths. Eight patients relapsed between 2 and 30 months after CR (median, 4.7 months). Forty-seven patients are alive in CR (45 first CR. 2 second CR) with a median follow-up of 57 months (24 t o 93 months). There were five toxicity-related deaths among patients in CR including four BMT-related deaths and five deaths caused by refractory relapses. One patient died in CR at 62 months of rectal cancer. The 3-year overall survival rate is 74% (SE = 5). According to the stages in the Murphy classification, the 3-year survival rates are stages I and II, 100%; stage 111,8O% (SE = 7); and stage IV and ALL, 57% (SE = 8). Seven of 12 patients with initial CNS disease are alive with a median survival of 56 months. The main toxic side effect was myelosuppression. The pediatric LMB protocol is suitable for and highly effective in adult patients. BMT does not seem necessary in patients in first CR. A prospective study including a large number of adult patients treated routinely with the LMB protocol will be necessary t o confirm these promising results. The chemotherapy regimen may need t o be moddied in certain respects for elderly patients. No consensus has been reached regarding the optimum treatment for these adult patients. In a retrospective study of 46 adults with SNCL treated in one center with various protocols, the results were better when a chemotherapy regimen similar to that of the pediatric protocol was used." Similar findings have been published by other authors.'" To confirm these observations, we reviewed the files of 65 adult patients with SNCL or ALL, treated with LMB protocols in 10 institutions.
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The main aims of the study were to compare the results with those obtained in children treated with the same protocol, as well as those of adults treated with other protocols, and to evaluate the toxicity and tolerance of the protocols when applied to adults. Abbreviations: RT. radiation therapy; CR', first complete remission; LMB84 + LMB86, LMB84 induction followed by LMB86 consolidation;
AutoBMT, autologous BMT; GI, gastrointestinal.
were a physical examination, a chest X-ray, abdominal ultrasonograaccording to the Murphy" and the Ann Arbo?' classifications. phy or computed tomography (CT), a complete blood count, bone
Throughout the text, the Murphy classification will be used for staging marrow aspiration or biopsy, and sampling of cerebrospinal fluid. unless otherwise indicated. According to these staging systems, the Other examinations were performed according to the clinical status.
disease is classified as ALL, when BM infiltration by L3 blasts (Bur Tables l through 4 indicate the stage of the disease for each patient kitt-like blast cells) is greater than 25% and 30%. respectively. that usually considerably reduces tumor bulk and allows metabolic disturbances to be managed while avoiding myelosuppression; induction started 1 week after the first day of COP and consisting of two consecutive courses of COPADM, ie, high-dose methotrexate (MTX) and cyclophosphamide (1.5 to 3 g/m*), with vincristine (2 mg), adriamycin (60 mglm'), and prednisone (60 mg/m2); a consolidation phase that varies, but always includes cytarabarine (100 mg/ m'/d) in a continuous infusion for 5 days; a maintenance therapy with the previous drugs whose length varied according to the studies.
CNS prophylaxis consists of chemotherapy alone (systemic highdose MTX and intrathecal MTX, cytarabine, and steroids): and no local irradiation is indicated.
In protocols LMB 81, 84, and 89 group B, the first two induction courses are identical with high-dose MTX given at the dosage of 3 g/m' in a 3-hour infusion. Consolidations are similar, but the difference is in the duration of maintenance therapy. The pediatric studies have shown the equivalence of these regimens, so from 1987 onward, the total duration of treatment has been shortened to 3.5 months. Because of poor results in patients with CNS disease and leukemic patients with LMB 81 and 84, more intensive protocols were designed for these patients, LMB 86 and LMB 89 group C. In the LMB 86 and LMB 89 group C protocols, high-dose MTX is given at the dosage of 8 g/m2 in a 4-hour infusion for induction courses, and the consolidation courses are intensified by the addition of high doses of cytarabine ( 3 g/m'/d; days 2 through 5 ) combined with etoposide in the CYVE (cytarabine, etoposide) course.' In the LMB 86 protocol, all patients received cranial irradiation. In LMB 89 group C, only patients with initial CNS disease were eligible for cranial irradiation. Therefore, since 1986, treatment for initial CNS disease has been based on systemic high-dose MTX, high-dose cytarabine, triple intrathecal injections, and cranial irradiation.
For reason of simplicity, the three protocols LMB 81, 84, and 89 group B are referred to as LMB 84, and the protocols LMB 86 and 89 group C are referred to as LMB 86, in the text and in the tables.
In the LMB 81, the treatment was the same for all patients. Then, according to the therapeutic results, patients received treatment of increasing intensity depending on the tumoral risk.
The LMB 84 protocol scheme was recommended by the SFOP for children with Murphy's nonabdominal stage 11, stage 111, and stage IV SNCL without CNS involvement. The LMB 86 protocol scheme was indicated for children with massive BM (>70% blasts) andor CNS involvement.
Response criteria. Complete remission (CR) was defined as the disappearance of all tumors at clinical examination, x-ray examination, ultrasonography or CT, normal lactate dehydrogenase activity, normal BM, and no evidence of CNS disease for at least 4 weeks.
Partial responses were defined as a greater than 50% reduction in the product of the perpendicular diameters of all measurable lesions for the same period.
Patients were considered to have refractory disease when they failed to achieve a partial response after first-line chemotherapy or when they partially responded to the latter, but showed disease progression during treatment. 25 Disease progression was the appearance of new lesions or an increase of more than 25% in existing lesions.
Toxicity was evaluated according to the Eastern Cooperative Oncology Group Scale criteria. Detailed information was available for the study of toxicity and tolerance for 300 cycles of a total of 330 cycles of chemotherapy.
Statistical analysis. The duration of survival was calculated from the date of diagnosis to death or the last date at which the patient was known to be alive. Event-free survival (EFS) and overall survival (OS) curves were plotted using the Kaplan-Meier method."
No multivariate analysis was conducted in this retrospective study because of the protocol violations.
RESULTS

Patients.
Sixty-five patients were included in this study. Twelve patients were over 40 years old. Sixty-two patients were European, one was North African, one was from the French West Indies, and one was from the Comoro Islands.
There were 46 males and 19 females (sex ratio 2,4: 1) with a median age of 26 years (range 17 to 65; mean, 30 years). The diagnoses were made between September 1984 and August 1991 and the analyses were effected in April 1994.
The lactate dehydrogenase (LDH) level was determined in 50 patients (77%). It was normal in 14 cases, twofold to threefold the normal value in 12 cases and more than three times the upper limit of the normal value in 24 cases.
The performance status (PS), known in 53 cases, was 0 in 14 cases, 1 to 2 in 26 cases, and 2 3 in 12 cases. Immunologic typing was performed in 32 cases (49%) and showed surface monoclonal Igs and antigens of B-cell lineage.
Initial karyotype determinations in 15 patients gave the following results: t(8,22), n = 2; t(8,14), n = 7; t(8,22) t(X,l), n = 1. The results were not evaluable for the re- The disease involved an abdominal extranodal site in 35 patients, the head and neck in 6 patients, nodes in 7 patients, the breast in l patient. Nine patients had isolated BM infiltration. Twelve patients had initial CNS infiltration (one isolated CNS', 2 with gastro-intestinal tract and no BM, 6 with BM alone, and 3 with BM and gastro-intestinal tract).
Cytohistopathology. All patients had a SNCL or ALL3. They were subtyped as Burkitt type in 48 cases and nonBurkitt in 10 cases. Seven cases could not be subclassified.
Treatment. Thirty-nine patients were treated according to the LMB 84 scheme (1 1 Murphy's stage I and 11, 19 stage 111, 2 stage IV, and 7 ALL3), 14 according to the LMB 86 scheme ( 2 stage III,2 stage IV, and 10 ALL,), and 12 patients (1 stage II,4 stage III,7 ALL,) received the induction course of the LMB 84 protocol followed by the LMB86 intensified consolidation regimen.
Nineteen patients (eight of whom had initial CNS involvement) underwent cranial irradiation as stated by the LMB 86 consolidation protocol. Three patients (1 stage 11, 1 stage 111, I ALL,) underwent a BMT with refractory disease and three patients (1 stage I, 1 stage 111, 1 ALL3) underwent a BMT in second CR.
Because its experience at that time was limited in adults and because of uncertainties concerning the prognosis of SNCL in adults, the medical team occasionally adopted approaches to treatment that sometimes were not in keeping with those of the LMB protocol in the belief that this would give patients a better chance of having a durable remission. This led to protocol violations. BM transplantation was systematically used in first CR for advanced disease in two centers (nos. 7 and 5): 13 patients ( 1 stage 11, 4 stage 111, 1 stage IV, 7 ALL3) in first CR after initial treatment according to an LMB protocol were subsequently shifted to a BMT program. Two patients with a stage 111 disease, treated with the LMB 84 regimen received an additional prophylactic cranial irradiation. Four patients (1 stage I, 1 stage II,2 stage 111) received local irradiation as part of the first line therapy.
The doses of MTX were reduced in 10 cases for fear of increased toxicity in adults.
Response to treatment. Fifty-eight patients (89%) achieved a CR. Three patients were not evaluable for response to treatment because of early treatment-related deaths. Four patients (6%) had primary refractory disease and died after 3, 4, 5, and 7 months. Eight patients (12%) relapsed (3 after BMT in first CR) after a median of 4.7 months (range, 2 to 30 months).
SOUSSAIN ET AL
Survival. With a median follow-up of 57 months [range, 24 to 93 months], 47 patients (72%) are alive in CR, including 2 in second CR. Eighteen patients died: three early toxicity-related deaths, nine caused by disease progression (four initial, five after relapse), five toxicity-related deaths while patients were in CR (including four after BMT), and one death caused by rectal cancer. The 3-year OS rate is 74% (SE = 5) for the whole population, and the 3-year EFS rate is 71 % (SE = 5) (Figs 1 and 2) .
Response to treatment, outcome, and survival are detailed
in Tables 2 through 5 Among the 58 patients in CR, 45 patients had no BMT and received the consolidation and maintenance chemotherapy according to the LMB protocol scheme, and I3 patients had a BMT while in first CR. The outcome of patients in each group is detailed in Table 6 . Forty of 45 patients (89%) who had no BMT in first CR are alive in CR (38 first CR and 2 second CR) with a median follow-up of 57 months. There were five relapses, one treatment-related death, and one death caused by rectal cancer. In the group of 13 patients who were shifted to a BMT program in first CR, 7 patients (54%) are alive in first CR (median follow-up, 61 months). There were three relapses and three BMT-related deaths. Rr1upse.s. Eight patients relapsed (Table 7) , 7 within the first year after diagnosis. One patient with Murphy's stage 1 relapsed locally. Four patients with Murphy's stage I11 disease relapsed. Two locally and two with a disseminated relapse. Two patients (nos. 26 and 31) had CNS disease at diagnosis and at relapse; they had received the LMB induction regimen followed by BMT after a conditioning regimen including total body irradiation and cyclophosphamide. One patient with ALLl relapsed in the BM. There were no isolated CNS relapses in the absence of initial CNS infiltration.
Three patients achieved a second CR: two of them received LMB chemotherapy as salvage treatment followed by allogeneic BMT in second CR, and one patient was treated by the MIME protocol" followed by local irradiation and an autologous BMT in second CR. One of these patients died while in second CR because of sepsis. The two others are alive in second CR at 34 and 91 months from the initial diagnosis, and at 32 and 61 months from the time of relapse. The other salvage treatments failed in five cases, and these five patients died.
The diagnosis of SNCL in patient no. 20, who developed the only late relapse, was confirmed initially (morphologic data) and at relapse (morphologic and karyotypic data). However, as karyotyping was not performed at initial diag- nosis, we cannot prove that the recurrence was caused by the same clone. Initial CNS involvement. Twelve patients had a CNS involvement at diagnosis, including three who had no concomitant BM involvement. There were two cases of isolated meningeal disease (nos. 26 and 31). Five patients experienced isolated cranial nerve palsy (nos. 19, 27, 37, 41, 47). Two patients (nos. 22 and 30) had cranial nerve palsy and an abnormal cranial CT scan. Patient no. 46 had cranial nerve palsy and abnormal cerebrospinal fluid. One patient (no. 5) had paraplegia, and another (no. 63), an epidural mass.
3-Year EFS
There were three early deaths (one treatment-related death and two initial treatment failures).
Nine patients achieved a CR. Six patients followed the LMB protocol and are cured. After the second induction course, three patients in first CR underwent a BMT with total body irradiation (TBI) and two of them had a relapse (no. 31 in the CNS, no. 26 in the CNS and BM) and subsequently died. Seven patients (58%) of 12 with an initial CNS disease are alive (median survival, 56 months).
BMT as salvage treatment. Three autologous procedures were performed in patients (nos. 1 1, 27, and 48) with refrac- No statistical analysis concerning the initial LDH, PS, and prognosis was performed because data were not available for all patients. We observed an equivalent rate of CR and relapse when patients had normal initial LDH level (13114, 3/13), or a level twofold to threefold (12/12, 0112) or more than three times the upper limit of normal (20/24, 3/20) . Patients with a poor initial performance status (PS 2 3) achieved a CR less frequently (8/12) than patients with a PS less than 3 (36/40) and had a higher incidence of treatment-related deaths (2/12 v 2/40).
No difference was noted in CR and relapse rates between Burkitt (44148, 6/44) and non-Burkitt types ( W O , US).
Tolerance and toxicity. Thirty-three patients underwent the full LMB 84 or LMB 86 protocols. Twenty patients received the LMB 84 chemotherapy regimen and the median duration of treatment was 16 weeks (1 1 to 36 weeks), for a For personal use only. on June 8, 2017 . by guest www.bloodjournal.org From , and 61) who routinely received reduced doses of MTX at the clinician's discretion to avoid toxicity instead of the LMB 86 regimen according to pediatric criteria do not appear to have fared worse because 9 of 10 are alive with no evidence of lymphoma. Cytarabine (Ara-C) and MTX dose modifications because of toxicitiy were necessary in eight (nos. 4, 10, 17, 20, 37, 42, 46, 63) of the patients who underwent full courses of chemotherapy. Three of these patients were over 40 and two of them experienced pancytopenia. The most severe toxic reactions are listed in Table 8 . The most frequent side effects caused by toxicity were fever and infection related to neutropenia. The median time spent in the hospital is given in Table 9 , together with the duration of neutropenia and antibiotherapy.
Twenty-two patients developed grade 111 or IV mucosi- Table 7 . Patterns of Relapses tis because of high-dose MTX, whereas two others had transient adverse reactions to high-dose Ara-C (cerebellar syndrome).
In the group of patients over 40, seven received the LMB 84 protocol. One toxicity-related death after COPADM courses was caused by sepsis (no. 62). Two patients required major drug dosage modifications (nos. 37 and 10) ( Table 8) . Four patients received the whole course of treament with no major side effects. One patients (no. 14) received the LMB 84 induction chemotherapy regimen followed by LMB 86 consolidation regimen and fared well. Four patients received the LMB 86 protocol. One patient (no. 28) died of a treatment-related toxicity, one patient (no. 17) experienced a prolonged pancytopenia, and two patients (nos. 5, 25) tolerated it well. The 65-year-old patient had systematic drug dose modifications, and experienced cerebellar toxicity at the end of the treatment. Two of four toxicity-related deaths occurred in patients over 40.
Sequelae, second tumor, and fertility after treatment. BM dysfunction persisted in two patients 30 months after Abbreviations: MAMl (27): Methyl-gag, high-dose Ara-C, Ifosfamide, Amsacrine; Cis-BMP, Cisplatin, Bleomycin, Methyl-gag, Methylprednisolone; Nov. novantrone; VIMl (15) . Ifosfamide. MTX, Etoposide; MIME, Methyl-gag, Ifosfamide, Methotrexate, Etoposide; RT, radiation therapy; CR', first complete remission; LMB84 + LMB86, LMB84 induction followed by LMB86 consolidation; autoBMT, autologous BMT.
AutoBMT
Death, 11 mo. sepsis
For the end of chemotherapy with no evidence of viral infection, and two patients experienced chronic graft-versus-host disease.
One patient (no. 66) experienced a T-cell ALL 17 months after the diagnosis of SNCL. He obtained a CR after a combination chemotherapy followed by a high-dose regimen and dogeneic BMT. He is still alive with no evidence of disease at 51 months. Another patient (no. 2) is under treatment for a cerebellar astrocytoma. Patient no. 17 died of rectal cancer while in CR of the SNCL. Patient no. 15 gave birth to a daughter five years after the completion of treatment, and patient no. 4 fathered a son born 7 years after the end of the treatment. 
DISCUSSION
The patients studied in this investigation had the typical clinical characteristics described in this disease. As with children, patients were predominantly male, and the disease was usually at an advanced stage at diagnosis.'.'' Abdominal extranodal sites were also predominant," accounting for 54% of cases. In contrast, such abdominal disease is generally only present in 36% of adult patients with non-Hodgkin's lymphomas regardless of the histologic type."
CNS involvement is generally associated with BM disease. Such was the case in 9 of the 12 patients with CNS involvement in our study. The incidence of CNS involvement (19%) and ALL3 (37%) was similar to that observed in large pediatric series.'
The Murphy classification was used in this study to permit comparisons with the results of pediatric series. Although the Ann Arbor classification is less appropriate for SNCL, which are commonly extranodal?**' it was also used for this analysis of results so that our findings could be compared with published adult trials.
The results we obtained in the adult patients with SNCL were similar ta those obtained in children? In addition, our results (89% CR and a 3-year survival rate of 74%) compare favorably with large series of adult patients with SNCL treated with conventional Patients over 40 also fared well: their CR and OS rates are 77% and 70%, respectively, and thus, comparable with those of patients under 40 (92% and 75%).
The on-going pediatric LMB 89 study' shows that Murphy's resected stage I and abdominal stage I1 can be cured by two courses of COPAD (oncovin, prednisone, cyclophosphamide, and adriarnycin). The good prognosis of very localized tumors has been reported in adults undergoing chemotherapy regimens similar to COPAD, with or without methotrexate.'6''8 In our series, the 12 patients with stage I or I1 disease are alive in CR. Five of them underwent complete surgical excision and were treated with the LMB 84 chemotherapy protocol. A shorter regimen may well prove to be effective in such cases, but this will have to be tested in a For personal use only. on June 8, 2017 . by guest www.bloodjournal.org From prospective trial. We observed one relapse in a patient with an extranodal, nonresected stage 1 disease localized in the breast. This patient had an uncommon disease site and, according to the pediatric criteria, would be treated by LMB 89 group B.
Results were very encouraging for patients with Murphy's stage 111 disease who attained a 3-year OS rate of 80% (SE = 7). The corresponding figures in pediatric series are 89% ? 20%.y
In the LMB 86 study, EFS among children with ALL3 was 76% 2 12 %. 4 Other studies of adult patients with ALL3 have yielded poor result^.'.^' Fenaux et a13* reported a 56% rate of CR (lo/] 8) and an OS rate of 3 1% at 1 1 months. Our results for patients with stage IV and ALL3 disease (57% 3-year OS) are encouraging. Moreover, these patients did not undergo uniform treatment (8 BMT in first CR) and most of the failures were in patients who underwent BMT in first CR (3 BMT toxicity-related deaths, two fatal relapses).
The rate of relapse (14%, 8/58) was relatively low. Seven of the eight relapses occurred within 1 year of diagnosis, as is usually the case in children with SNCL.16,"-''
Previous pediatric LMB studies showed that CNS prophylaxis with chemotherapy alone (high-dose MTX + intrathecal [IT] MTX) can reduce the rate of isolated CNS relapse to less than 3%."." Our results support this latter figure because no case of isolated CNS relapse was observed among the patients who received CNS prophylaxis, although some patients received cranial RT in the absence of isolated CNS involvement in addition to high-dose systemic chemotherapy.
In the group of 12 patients with an initial CNS disease, 1 died of early toxicity. Eleven patients are evaluable for treatment response and 7 of them are alive. Six patients received the whole course of chemotherapy with high-dose MTX (3 or 8 g/m2), high-dose cytarabine and cranial irradiation. One of the 3 patients engrafted is alive, and the 2 others died of a relapse (one isolated in the CNS and one in the CNS and BM). Patients were engrafted after consolidation chemotherapy, and did not receive high-dose cytarabine. Thus, three of four treament failures (initial and relapses) were in patients who did not receive CYVE courses, although pediatric studies have emphasized the importance of high-dose MTX and high-dose cytarabine in cases of CNS di~ease.'~ The results of our series reflect the importance of these two drugs. On the other hand, firm conclusions cannot be drawn regarding the necessity of cranial irradiation because all patients alive had received irradiation, either cranial (five cases) or TB1 (one case).
In the LMB protocol, BMT is not indicated for children in first CR from SNCL or ALL3. 24 For adults, the role of BMT in this disease is still debated.36.37 In our series, the survival rate was 54% (7/13) among those who underwent BMT in first CR and 89% (40/45) for those in CR who did not. Although it could be argued that because BMT was not used prospectively, statistical comparisons are not possible, the use of BMT is not recommended for adult patients in first CR from SNCL.
We also confirm that patients with refractory lymphomas are poor candidates for BMT,25,36,38,39 in contrast with both adults and children with chemosensitive relapses and partial
As described in Table 9 , the main toxicity was hematologic, with 90% of patients developing profound granulocytopenia after COPADM and CYVE courses.Three patients died of sepsis. Aplasia almost always occurs also in children" after the COPADM (80% to 90% of cases) with frequent episodes of fever and severe infection in 80% and 20% to 30% of cases, respectively. CYM courses are responsible for aplasia in 20% to 30% of cases. After CYVE courses (Catherine Patte, personal communication), aplasia occurs in about 90% of cases. Toxicity in these adult patients was similar to that reported in children and was less severe than with other adult protocols." One possible explanation is that the median age of the population was relatively low (26 years) and that the dose of MTX was reduced from 8 to 3 g/m2 in some cases. The use of hematopoietic growth factors may circumvent this myelotoxicity in the future.
In conclusion, this retrospective study on 65 patients shows that the treatment of SNCL with the pediatric LMB protocols yields better results than those previously obtained with other protocols. Therefore, the LMB protocols are feasible for adult patients and are not more toxic than in children. Dose adjustments remain to be defined for elderly patients. As patients over 40 were treated in the majority of cases with the induction course of LMB 84 with satisfactory results, and because of the toxicity of high-dose Ara-C encountered in elderly patients, in our prospective protocol we recommend an MTX dose of 3 g/m2 and an Ara-C dose of 2 g/mZ for patients between 40 and 60, and MTX and Ara-C doses of 1 g/m2 for those over 60.
These results must now be confirmed in a prospective trial.
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